{"transactions":[{"id":730578,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":4,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":5,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":6,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":7,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":9,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":10,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T20:00:07.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with BP Directors, LP (\"Bios Directors\"), Dr. Fletcher has agreed that he will hold certain equity-based awards granted to him in connection with his services as a director of the Issuer merely as a nominee for Bios Directors. Bios Directors may be deemed the direct or indirect beneficial owner of the reported securities, and Bios Equity Partners, LP (\"Bios Equity I\"), Cavu Management, LP (\"Cavu Management\"), Bios Capital Management, LP (\"Bios Management\"), Cavu Advisors LLC (\"Cavu Advisors\"), Bios Advisors GP, LLC (\"Bios Advisors\"), Leslie W. Kreis, Jr. (\"Mr. Kreis\") and Dr. Fletcher may each be deemed the indirect beneficial owner of the reported securities through his or its respective indirect interest in Bios Directors."}],"balance_after":81229,"source":{"system":"sec-edgar","filing":"0001789490-26-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000178949026000002/primary_doc.xml","form_type":"4"}},{"id":1105083,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":4,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":5,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":6,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":7,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":9,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":10,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T21:38:56.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 18, 2026 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to Aaron G.L. Fletcher's (\"Dr. Fletcher\") continuous service as a director as of the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with BP Directors, LP (\"Bios Directors\"), Dr. Fletcher has agreed that he will hold certain equity-based awards granted to him in connection with his services as a director of the Issuer merely as a nominee for Bios Directors. Bios Directors may be deemed the direct or indirect beneficial owner of the reported securities, and Bios Equity Partners, LP (\"Bios Equity I\"), Cavu Management, LP (\"Cavu Management\"), Bios Capital Management, LP (\"Bios Management\"), Cavu Advisors LLC (\"Cavu Advisors\"), Bios Advisors GP, LLC (\"Bios Advisors\"), Leslie W. Kreis, Jr. (\"Mr. Kreis\") and Dr. Fletcher may each be deemed the indirect beneficial owner of the reported securities through his or its respective indirect interest in Bios Directors."}],"balance_after":48500,"source":{"system":"sec-edgar","filing":"0001104659-25-061241","document":"tm2518563-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925061241/tm2518563-1_4seq1.xml","form_type":"4"}},{"id":1483625,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":4,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":5,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":6,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":7,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":9,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":10,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-12T01:32:56.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option vests in full on the earlier of (i) June 7, 2025 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to Dr. Fletcher's continuous service as a director as of the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with BP Directors, LP (\"Bios Directors\"), Dr. Fletcher has agreed that he will hold certain equity-based awards granted to him in connection with his services as a director of the Issuer merely as a nominee for Bios Directors. Bios Directors may be deemed the direct or indirect beneficial owner of the reported securities, and Bios Equity Partners, LP (\"Bios Equity I\"), Cavu Management, LP (\"Cavu Management\"), Bios Capital Management, LP (\"Bios Management\"), Cavu Advisors LLC (\"Cavu Advisors\"), Bios Advisors GP, LLC (\"Bios Advisors\"), Leslie W. Kreis, Jr. (\"Mr. Kreis\") and Dr. Fletcher may each be deemed the indirect beneficial owner of the reported securities through his or its respective indirect interest in Bios Directors."}],"balance_after":8500,"derivative":{"exercise_price":1.95,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001104659-24-070572","document":"tm2416970-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465924070572/tm2416970-1_4seq1.xml","form_type":"4"}},{"id":1483624,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":4,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":5,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":6,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":7,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":9,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":10,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-12T01:32:56.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 7, 2025 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to Aaron G.L. Fletcher's (\"Dr. Fletcher\") continuous service as a director as of the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with BP Directors, LP (\"Bios Directors\"), Dr. Fletcher has agreed that he will hold certain equity-based awards granted to him in connection with his services as a director of the Issuer merely as a nominee for Bios Directors. Bios Directors may be deemed the direct or indirect beneficial owner of the reported securities, and Bios Equity Partners, LP (\"Bios Equity I\"), Cavu Management, LP (\"Cavu Management\"), Bios Capital Management, LP (\"Bios Management\"), Cavu Advisors LLC (\"Cavu Advisors\"), Bios Advisors GP, LLC (\"Bios Advisors\"), Leslie W. Kreis, Jr. (\"Mr. Kreis\") and Dr. Fletcher may each be deemed the indirect beneficial owner of the reported securities through his or its respective indirect interest in Bios Directors."}],"balance_after":14500,"source":{"system":"sec-edgar","filing":"0001104659-24-070572","document":"tm2416970-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465924070572/tm2416970-1_4seq1.xml","form_type":"4"}},{"id":1744132,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":4,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":5,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":6,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":7,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":9,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":10,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-13T14:47:16.000Z","date":"2023-11-08","kind":"grant","planned":false,"acquired":true,"shares":500095,"price":1.05,"value":525099.75,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 8, 2023, Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") purchased 500,095 shares of Common Stock in an at-the-market offering through Cantor Fitzgerald & Co. and B. Riley Securities, Inc. acting as sales agents."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF Fund. Bios Management is the general partner of Bios Equity COF. Dr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF Fund. Because of the relationship between Dr. Fletcher, Bios Management, Bios Advisors and Bios COF Fund, Dr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the shares held directly by Bios COF Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each reporting person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such reporting person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":500095,"source":{"system":"sec-edgar","filing":"0001104659-23-116868","document":"tm2330521-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465923116868/tm2330521-2_4seq1.xml","form_type":"4"}},{"id":1857341,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":4,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":5,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":6,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":7,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":9,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":10,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-14T00:01:05.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests in full on the earlier of (i) June 9, 2024 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to Dr. Fletcher's continuous service as a director as of the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with BP Directors, LP (\"Bios Directors\"), Dr. Fletcher has agreed that he will hold certain equity-based awards granted to him in connection with his services as a director of the Issuer merely as a nominee for Bios Directors. Bios Directors may be deemed the direct or indirect beneficial owner of the reported securities, and Bios Equity Partners, LP (\"Bios Equity I\"), Cavu Management, LP (\"Cavu Management\"), Bios Capital Management, LP (\"Bios Management\"), Cavu Advisors LLC (\"Cavu Advisors\"), Bios Advisors GP, LLC (\"Bios Advisors\"), Leslie W. Kreis, Jr. (\"Mr. Kreis\") and Dr. Fletcher may each be deemed the indirect beneficial owner of the reported securities through his or its respective indirect interest in Bios Directors."}],"balance_after":6000,"derivative":{"exercise_price":2.77,"expiration_date":"2033-06-09","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001104659-23-070932","document":"tm2318644-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465923070932/tm2318644-1_4seq1.xml","form_type":"4"}},{"id":1857340,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":4,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":5,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":6,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":7,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":9,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":10,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-14T00:01:05.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 9, 2024 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to Aaron G.L. Fletcher's (\"Dr. Fletcher\") continuous service as a director as of the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with BP Directors, LP (\"Bios Directors\"), Dr. Fletcher has agreed that he will hold certain equity-based awards granted to him in connection with his services as a director of the Issuer merely as a nominee for Bios Directors. Bios Directors may be deemed the direct or indirect beneficial owner of the reported securities, and Bios Equity Partners, LP (\"Bios Equity I\"), Cavu Management, LP (\"Cavu Management\"), Bios Capital Management, LP (\"Bios Management\"), Cavu Advisors LLC (\"Cavu Advisors\"), Bios Advisors GP, LLC (\"Bios Advisors\"), Leslie W. Kreis, Jr. (\"Mr. Kreis\") and Dr. Fletcher may each be deemed the indirect beneficial owner of the reported securities through his or its respective indirect interest in Bios Directors."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001104659-23-070932","document":"tm2318644-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465923070932/tm2318644-1_4seq1.xml","form_type":"4"}},{"id":2102606,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":4,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":5,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":6,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":7,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":9,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":10,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-29T12:02:22.000Z","date":"2022-11-28","kind":"purchase","acquired":true,"shares":1871,"price":2.6497,"value":4957.5887,"ownership":{"direct":false,"nature":"By Bios Fund III, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.64 to $2.65, inclusive. The reporting persons undertake to provide to Cognition Therapeutics Inc., any security holder of Cognition Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and Bios Memory SPV I, LP (\"Bios Memory I\").  Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Memory SPV II, LP (\"Bios Memory II\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Memory SPV I, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Memory II, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":309748,"source":{"system":"sec-edgar","filing":"0001104659-22-122625","document":"tm2231503-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465922122625/tm2231503-2_4seq1.xml","form_type":"4"}},{"id":2102605,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":4,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":5,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":6,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":7,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":9,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":10,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-29T12:02:22.000Z","date":"2022-11-28","kind":"purchase","acquired":true,"shares":12220,"price":2.6497,"value":32379.334,"ownership":{"direct":false,"nature":"By Bios Fund III QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.64 to $2.65, inclusive. The reporting persons undertake to provide to Cognition Therapeutics Inc., any security holder of Cognition Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and Bios Memory SPV I, LP (\"Bios Memory I\").  Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Memory SPV II, LP (\"Bios Memory II\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Memory SPV I, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Memory II, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":2021906,"source":{"system":"sec-edgar","filing":"0001104659-22-122625","document":"tm2231503-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465922122625/tm2231503-2_4seq1.xml","form_type":"4"}},{"id":2102604,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":4,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":5,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":6,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":7,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":9,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":10,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-29T12:02:22.000Z","date":"2022-11-28","kind":"purchase","acquired":true,"shares":1973,"price":2.6497,"value":5227.8581,"ownership":{"direct":false,"nature":"By Bios Fund III NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.64 to $2.65, inclusive. The reporting persons undertake to provide to Cognition Therapeutics Inc., any security holder of Cognition Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and Bios Memory SPV I, LP (\"Bios Memory I\").  Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Memory SPV II, LP (\"Bios Memory II\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Memory SPV I, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Memory II, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":326733,"source":{"system":"sec-edgar","filing":"0001104659-22-122625","document":"tm2231503-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465922122625/tm2231503-2_4seq1.xml","form_type":"4"}},{"id":2112365,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":4,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":5,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":6,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":7,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":9,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":10,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-17T12:00:50.000Z","date":"2022-11-16","kind":"purchase","acquired":true,"shares":8269,"price":1.4,"value":11576.6,"ownership":{"direct":false,"nature":"Bios Fund III, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.23 to $1.54, inclusive. The reporting persons undertake to provide to Cognition Therapeutics Inc., any security holder of Cognition Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and Bios Memory SPV I, LP (\"Bios Memory I\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Memory SPV II, LP (\"Bios Memory II\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kries, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Memory SPV I, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Memory II, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kries, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kries, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":307877,"source":{"system":"sec-edgar","filing":"0001104659-22-119721","document":"tm2230532-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465922119721/tm2230532-4_4seq1.xml","form_type":"4"}},{"id":2112364,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":4,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":5,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":6,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":7,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":9,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":10,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-17T12:00:50.000Z","date":"2022-11-16","kind":"purchase","acquired":true,"shares":54009,"price":1.4,"value":75612.6,"ownership":{"direct":false,"nature":"By Bios Fund III QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.23 to $1.54, inclusive. The reporting persons undertake to provide to Cognition Therapeutics Inc., any security holder of Cognition Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and Bios Memory SPV I, LP (\"Bios Memory I\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Memory SPV II, LP (\"Bios Memory II\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kries, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Memory SPV I, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Memory II, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kries, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kries, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":2009686,"source":{"system":"sec-edgar","filing":"0001104659-22-119721","document":"tm2230532-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465922119721/tm2230532-4_4seq1.xml","form_type":"4"}},{"id":2112363,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":4,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":5,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":6,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":7,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":9,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":10,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-17T12:00:50.000Z","date":"2022-11-16","kind":"purchase","acquired":true,"shares":8722,"price":1.4,"value":12210.8,"ownership":{"direct":false,"nature":"By Bios Fund III NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.23 to $1.54, inclusive. The reporting persons undertake to provide to Cognition Therapeutics Inc., any security holder of Cognition Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and Bios Memory SPV I, LP (\"Bios Memory I\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Memory SPV II, LP (\"Bios Memory II\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kries, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Memory SPV I, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Memory II, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kries, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kries, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":324760,"source":{"system":"sec-edgar","filing":"0001104659-22-119721","document":"tm2230532-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465922119721/tm2230532-4_4seq1.xml","form_type":"4"}},{"id":2114686,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":4,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":5,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":6,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":7,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":9,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":10,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-16T12:00:45.000Z","date":"2022-11-15","kind":"purchase","acquired":true,"shares":174700,"price":1.2,"value":209640.0,"ownership":{"direct":false,"nature":"Bios Fund III, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and Bios Memory SPV I, LP (\"Bios Memory I\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general\npartner of the following entities: Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Memory SPV II, LP (\"Bios Memory II\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner\nof the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general\npartners Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Management and Bios Advisors are entities managed and controlled by\nAaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kries, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Memory SPV I, Bios Fund II, Bios Fund II QP, Bios Fund II\nNT, Bios Memory II, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kries, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity\nEntities, Mr. Kries, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission\nthat such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":299608,"source":{"system":"sec-edgar","filing":"0001104659-22-119341","document":"tm2230532-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465922119341/tm2230532-2_4seq1.xml","form_type":"4"}},{"id":2114685,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":4,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":5,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":6,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":7,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":9,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":10,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-16T12:00:45.000Z","date":"2022-11-15","kind":"purchase","acquired":true,"shares":1141030,"price":1.2,"value":1369236.0,"ownership":{"direct":false,"nature":"By Bios Fund III QP, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and Bios Memory SPV I, LP (\"Bios Memory I\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general\npartner of the following entities: Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Memory SPV II, LP (\"Bios Memory II\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner\nof the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general\npartners Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Management and Bios Advisors are entities managed and controlled by\nAaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kries, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Memory SPV I, Bios Fund II, Bios Fund II QP, Bios Fund II\nNT, Bios Memory II, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kries, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity\nEntities, Mr. Kries, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission\nthat such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":1955677,"source":{"system":"sec-edgar","filing":"0001104659-22-119341","document":"tm2230532-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465922119341/tm2230532-2_4seq1.xml","form_type":"4"}},{"id":2114684,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":4,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":5,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":6,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":7,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":9,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":10,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-16T12:00:45.000Z","date":"2022-11-15","kind":"purchase","acquired":true,"shares":184270,"price":1.2,"value":221124.0,"ownership":{"direct":false,"nature":"By Bios Fund III NT, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and Bios Memory SPV I, LP (\"Bios Memory I\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general\npartner of the following entities: Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Memory SPV II, LP (\"Bios Memory II\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner\nof the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general\npartners Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Management and Bios Advisors are entities managed and controlled by\nAaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kries, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Memory SPV I, Bios Fund II, Bios Fund II QP, Bios Fund II\nNT, Bios Memory II, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kries, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity\nEntities, Mr. Kries, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission\nthat such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":316038,"source":{"system":"sec-edgar","filing":"0001104659-22-119341","document":"tm2230532-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465922119341/tm2230532-2_4seq1.xml","form_type":"4"}},{"id":2420159,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78302,"kind":"person","name":"BIOS Memory SPV II, LP","position":7,"cik":"0001666485","reported_name":"BIOS Memory SPV II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":8,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":9,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":10,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-01T19:24:57.000Z","date":"2021-10-13","kind":"exercise","acquired":true,"shares":1424014,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This line item is being re-reported here to gain access to the filing system for purposes of filing this amendment (this \"Amendment\") to the Form 4 filed by Bios Memory SPV I, LP on October 15, 2021 (the \"Original Filing\").  This Amendment is being filed to (i)  add certain persons identified in the Original Filing as Reporting Persons and (ii) further describe the relationships between the Reporting Persons in footnotes 3, 4 and 5 of this Amendment."},{"field":"security","element":"securityTitle","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of Bios Fund I, LP and Bios Fund I QP, LP.  Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP, Bios Fund II QP, LP, Bios Fund II NT, LP, and Bios Memory SPV II, LP.  Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of Bios Fund III, LP, Bios Fund III NT, LP, and Bios Fund III QP, LP.  Cavu Management, LP (\"Cavu Management\") and Bios Capital Management, LP (\"Bios Management\") are the general partners of Bios Equity I, Bios Equity II, Bios Equity III and Bios Memory SPV I, LP.  Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Leslie W. Kreis, is the general partner of Cavu Management.  Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Dr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"security","element":"securityTitle","label":"F4","text":"Dr. Fletcher, Mr. Kreis, Bios Advisors, Cavu Advisors, Bios Management and Cavu Management each share voting and investment control with respect to the shares held by the following entities: Bios Memory SPV I, LP, Bios Fund I, LP, Bios Fund I QP, LP,  Bios Fund II, LP, Bios Fund II QP, LP, Bios Fund II NT, LP, Bios Memory SPV II, LP, Bios Fund III, LP, Bios Fund III NT, LP, and Bios Fund III QP, LP (collectively, the \"Bios Equity Entities\").  Because of the relationship between Dr. Fletcher, Mr. Kreis, Bios Advisors, Cavu Advisors, Bios Management, Cavu Management and the Bios Equity Entities, each of Dr. Fletcher, Mr. Kreis, Bios Advisors, Cavu Advisors, Bios Management and Cavu Management may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"security","element":"securityTitle","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B Convertible Preferred Stock converted into Cognition Therapeutics, Inc. (\"CGTX\") common stock upon the closing of the issuer's initial public offering (\"IPO\"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":1424014,"source":{"system":"sec-edgar","filing":"0001643749-22-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000164374922000002/primary_doc.xml","form_type":"4/A","original_submission_date":"2021-10-15"}},{"id":2541603,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Simple Agreement for Future Equity","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":false,"shares":25593,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bios Fund III, NT, LP."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Simple Agreement for Future Equity converted into CGTX common stock upon the closing of the issuer's IPO at 80% of the per share offering price of the IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Simple Agreement for Future Equity converted into CGTX common stock upon the closing of the issuer's IPO at 80% of the per share offering price of the IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Simple Agreement for Future Equity converted into CGTX common stock upon the closing of the issuer's IPO at 80% of the per share offering price of the IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":0,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":32,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541602,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Simple Agreement for Future Equity","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":false,"shares":158476,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bios Fund III, QP, LP."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Simple Agreement for Future Equity converted into CGTX common stock upon the closing of the issuer's IPO at 80% of the per share offering price of the IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Simple Agreement for Future Equity converted into CGTX common stock upon the closing of the issuer's IPO at 80% of the per share offering price of the IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Simple Agreement for Future Equity converted into CGTX common stock upon the closing of the issuer's IPO at 80% of the per share offering price of the IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":0,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":31,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541601,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Simple Agreement for Future Equity","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":false,"shares":24263,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bios Fund III, LP."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Simple Agreement for Future Equity converted into CGTX common stock upon the closing of the issuer's IPO at 80% of the per share offering price of the IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Simple Agreement for Future Equity converted into CGTX common stock upon the closing of the issuer's IPO at 80% of the per share offering price of the IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Simple Agreement for Future Equity converted into CGTX common stock upon the closing of the issuer's IPO at 80% of the per share offering price of the IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":0,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541600,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"other","acquired":false,"shares":33495,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bios Memory SPV II, LP."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The warrant expires on the earliest of (i) March 15, 2023, (ii) upon a liquidation, dissolution or winding up of the Company, (iii) the closing of a Sale Transaction (as defined in the warrant), (iv) upon the closing of the issuer's IPO or (v) upon repayment of a promissory note issued in connection with the warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The warrant expires on the earliest of (i) March 15, 2023, (ii) upon a liquidation, dissolution or winding up of the Company, (iii) the closing of a Sale Transaction (as defined in the warrant), (iv) upon the closing of the issuer's IPO or (v) upon repayment of a promissory note issued in connection with the warrant."}],"balance_after":0,"derivative":{"exercise_price":0.032,"exercise_date":"2016-03-15","expiration_date":"2023-03-15","underlying":"Common Stock","underlying_shares":33495},"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541599,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":false,"shares":111504,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bios Fund III, NT, LP."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":34472},"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541598,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":false,"shares":1930673,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bios Fund III, QP, LP."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":596899},"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541597,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":false,"shares":134626,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bios Fund III, LP."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":41620},"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541596,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":false,"shares":110744,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bios Fund II, NT, LP."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":34238},"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541595,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":false,"shares":1138040,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bios Memory SPV II, LP."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":351844},"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541594,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":false,"shares":827275,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bios Fund II, QP, LP."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":255765},"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541593,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":false,"shares":253256,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bios Fund II, LP."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":78298},"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541592,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":false,"shares":792547,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bios Fund I, QP, LP."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Convertible Preferred Stock converted into Cognition Therapeutics, Inc. (\"CGTX\") common stock upon the closing of the issuer's initial public offering (\"IPO\"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Convertible Preferred Stock converted into Cognition Therapeutics, Inc. (\"CGTX\") common stock upon the closing of the issuer's initial public offering (\"IPO\"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Convertible Preferred Stock converted into Cognition Therapeutics, Inc. (\"CGTX\") common stock upon the closing of the issuer's initial public offering (\"IPO\"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":245029},"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541591,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":false,"shares":1355017,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bios Fund I, LP."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Convertible Preferred Stock converted into Cognition Therapeutics, Inc. (\"CGTX\") common stock upon the closing of the issuer's initial public offering (\"IPO\"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Convertible Preferred Stock converted into Cognition Therapeutics, Inc. (\"CGTX\") common stock upon the closing of the issuer's initial public offering (\"IPO\"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Convertible Preferred Stock converted into Cognition Therapeutics, Inc. (\"CGTX\") common stock upon the closing of the issuer's initial public offering (\"IPO\"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":418926},"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541590,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":false,"shares":4605985,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Convertible Preferred Stock converted into Cognition Therapeutics, Inc. (\"CGTX\") common stock upon the closing of the issuer's initial public offering (\"IPO\"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Convertible Preferred Stock converted into Cognition Therapeutics, Inc. (\"CGTX\") common stock upon the closing of the issuer's initial public offering (\"IPO\"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Convertible Preferred Stock converted into Cognition Therapeutics, Inc. (\"CGTX\") common stock upon the closing of the issuer's initial public offering (\"IPO\"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1424014},"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541589,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":true,"shares":25593,"ownership":{"direct":false,"nature":"By Bios Fund III, NT, LP."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Simple Agreement for Future Equity converted into CGTX common stock upon the closing of the issuer's IPO at 80% of the per share offering price of the IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":60065,"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541588,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":true,"shares":34472,"ownership":{"direct":false,"nature":"By Bios Fund III, NT, LP."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":34472,"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541587,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"purchase","acquired":true,"shares":144530,"price":12,"value":1734360.0,"ownership":{"direct":false,"nature":"By Bios Fund III, QP, LP."},"balance_after":899905,"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541586,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":true,"shares":158476,"ownership":{"direct":false,"nature":"By Bios Fund III, QP, LP."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Simple Agreement for Future Equity converted into CGTX common stock upon the closing of the issuer's IPO at 80% of the per share offering price of the IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":755375,"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541585,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":true,"shares":596899,"ownership":{"direct":false,"nature":"By Bios Fund III, QP, LP."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":596899,"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541584,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"purchase","acquired":true,"shares":22129,"price":12,"value":265548.0,"ownership":{"direct":false,"nature":"By Bios Fund III, LP."},"balance_after":88012,"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541583,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":true,"shares":24263,"ownership":{"direct":false,"nature":"By Bios Fund III, LP."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Simple Agreement for Future Equity converted into CGTX common stock upon the closing of the issuer's IPO at 80% of the per share offering price of the IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":65883,"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541582,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":true,"shares":41620,"ownership":{"direct":false,"nature":"By Bios Fund III, LP."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":41620,"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541581,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"sale","acquired":false,"shares":90.28,"price":12,"value":1083.36,"ownership":{"direct":false,"nature":"By Bios Memory SPV II, LP."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On October 13, 2021, the reporting person exercised a warrant to purchase 33,495 shares of CGTX common stock for $0.032 per share. The reporting person paid the exercise price on a cashless basis, resulting in CGTX's withholding of 90.28 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 33,404 shares. The issuer paid cash to the reporting person in lieu of any fractional share amounts."}],"balance_after":385248,"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541580,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"other","acquired":true,"shares":33495,"price":0.032,"value":1071.84,"ownership":{"direct":false,"nature":"By Bios Memory SPV II, LP."},"balance_after":385339,"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541579,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":true,"shares":351844,"ownership":{"direct":false,"nature":"By Bios Memory SPV II, LP."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":351844,"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541578,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"purchase","acquired":true,"shares":23341,"price":12,"value":280092.0,"ownership":{"direct":false,"nature":"By Bios Fund II, NT, LP."},"balance_after":57579,"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541577,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":true,"shares":34238,"ownership":{"direct":false,"nature":"By Bios Fund II, NT, LP."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":34238,"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541576,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":true,"shares":255765,"ownership":{"direct":false,"nature":"By Bios Fund II, QP, LP."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":255765,"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541575,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":true,"shares":78298,"ownership":{"direct":false,"nature":"By Bios Fund II, LP."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":78298,"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541574,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":true,"shares":245029,"ownership":{"direct":false,"nature":"By Bios Fund I, QP, LP."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Convertible Preferred Stock converted into Cognition Therapeutics, Inc. (\"CGTX\") common stock upon the closing of the issuer's initial public offering (\"IPO\"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":245029,"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541573,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":true,"shares":418926,"ownership":{"direct":false,"nature":"By Bios Fund I, LP."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Convertible Preferred Stock converted into Cognition Therapeutics, Inc. (\"CGTX\") common stock upon the closing of the issuer's initial public offering (\"IPO\"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":418926,"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}},{"id":2541572,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":1,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-16T01:54:18.000Z","date":"2021-10-13","kind":"exercise","acquired":true,"shares":1424014,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Convertible Preferred Stock converted into Cognition Therapeutics, Inc. (\"CGTX\") common stock upon the closing of the issuer's initial public offering (\"IPO\"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration."}],"balance_after":1424014,"source":{"system":"sec-edgar","filing":"0001104659-21-126906","document":"tm2130061-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921126906/tm2130061-6_4seq1.xml","form_type":"4"}}]}